Results 51 to 60 of about 79,327 (229)
Frontiers in Immunology, 2020 The RTS,S/AS01 vaccine provides partial protection against Plasmodium falciparum infection but determinants of protection and/or disease are unclear. Previously, anti-circumsporozoite protein (CSP) antibody titers and blood RNA signatures were associated
Ying Du +19 more
doaj +1 more source
Recent advances in malaria genomics and epigenomics [PDF]
, 2016 Malaria continues to impose a significant disease burden on low- and middle-income countries in the tropics. However, revolutionary progress over the last 3 years in nucleic acid sequencing, reverse genetics, and post-genome analyses has generated step ...
Kirchner, Sebastian +2 more
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar +6 more
wiley +1 more source
RTS,S/AS02 and the quest of the Holy Grail [PDF]
, 2002 High-profile programs under the WHO/Roll Back Malaria initiative, in addition to unravelling the human and malaria parasite genomes, have ensured that malaria vaccine research and development are enjoying an unprecedented boom. So far, the development of
Reithinger, R
core
Theoretical implications of a pre-erythrocytic Plasmodium vivax vaccine for preventing relapses [PDF]
, 2017 Preventing malaria infection through vaccination requires preventing every sporozoite inoculated by mosquito bite: a major challenge for Plasmodium falciparum.
Amino, R, Mueller, I, White, MT
core +3 more sources
Biotechnology and Bioengineering, EarlyView.SpyCatcher‐mi3 nanoparticles displaying RBD‐SD1 from MERS‐CoV, NL140422, and HKU4 elicited robust and cross‐reactive IgG responses in mice. Only MERS‐CoV RBD‐SD1 induced neutralizing antibodies against MERS‐CoV and protected human DPP4 mice from a MERS‐CoV challenge, indicating conserved serologic but limited cross‐neutralizing epitopes.
Peter J. Halfmann +9 more
wiley +1 more source
The Lancet, 2004 Large gains in the reduction of malaria mortality in the early 20th century were lost in subsequent decades. Malaria now kills 2-3 million people yearly. Implementation of malaria control technologies such as insecticide-treated bednets and chemotherapy could reduce mortality substantially, but an effective malaria vaccine is also needed.
Moorthy, V, Good, M, Hill, A
openaire +3 more sources
Health Economics, EarlyView.ABSTRACT Evidence on the relationship between public health expenditure and health is mixed and particularly scarce for low‐income countries. Existing studies overlook the subnational distribution of expenditure and rarely distinguish between sources and governance over funding.
Eliana Chavarría‐Pino +3 more
wiley +1 more source
Scientific ReportsThe Plasmodium falciparum cysteine-rich protective antigen (PfCyRPA) is a promising target as a next-generation blood-stage malaria vaccine and together with PCRCR complex members, the reticulocyte binding-like homologous protein 5 (PfRh5) and the Rh5 ...
Aboubacar Ba +19 more
doaj +1 more source
Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites. [PDF]
PLoS ONE, 2012 Live attenuated malaria vaccines are more potent than the recombinant protein, bacterial or viral platform vaccines that have been tested, and an attenuated sporozoite vaccine against falciparum malaria is being developed for humans.
Walter R Weiss, Chengyong George Jiang
doaj +1 more source